SynBioBeta Speaker
Alexandra Brocato
Beakr
CEO & Co-founder
Ali Brocato is the co-founder and CEO of Beakr, an AI platform that learns how life sciences teams actually work and turns that into executable knowledge - making experimentation computable, reusable, and compounding. She completed a combined BS/MS in Biomedical Engineering at Yale in three and a half years, building two companies along the way: Simplex Sciences, now the largest supplier of ssDNA ladders to academic and industry labs, and ADVANCE, an AI-powered nurse-patient communication platform with Yale New Haven Health. She published her first research at 17 during a study at the Harvard Stem Cell Institute. Most recently before Beakr, Ali was a growth investor at General Atlantic evaluating software and healthtech companies - giving her a rare vantage point as a founder who has built, published, and invested across the life sciences stack.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Alexandra
This Year
•
-
General
Women of SynBio: Connect, Share, Lead
Grab a seat at the table with women from across the synthetic biology community for an engaging and welcoming luncheon. Designed for connection and conversation, this gathering brings together founders, scientists, operators, and rising talent to share experiences, spark ideas, and build lasting relationships. Expect thoughtful dialogue, new connections, and a supportive space to grow together.
Get a Ticket
•
-
General
Women of SynBio: Connect, Share, Lead
Grab a seat at the table with women from across the synthetic biology community for an engaging and welcoming luncheon. Designed for connection and conversation, this gathering brings together founders, scientists, operators, and rising talent to share experiences, spark ideas, and build lasting relationships. Expect thoughtful dialogue, new connections, and a supportive space to grow together.
Get a Ticket
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
